Status:

COMPLETED

Long-term Safety and Effectiveness of OROS Methylphenidate HCl in Children With Attention Deficit Hyperactivity Disorder

Lead Sponsor:

Alza Corporation, DE, USA

Conditions:

Attention Deficit Hyperactivity Disorder

Eligibility:

All Genders

6-13 years

Phase:

PHASE3

Brief Summary

The purpose of this study is to evaluate the long-term safety and effectiveness of OROS® Methylphenidate HCl (a central nervous system stimulant) in children with attention deficit hyperactivity diso...

Detailed Description

Attention Deficit Hyperactivity Disorder (ADHD) represents the most common neurobehavioral disorder in children, affecting 3% to 5% of the school-age population. Behavioral pediatricians, child psychi...

Eligibility Criteria

Inclusion

  • Patients who have successfully completed one of the following earlier ALZA studies: CR005992, C-97-033 (and then successfully completed C-98-011), CR005989, or CR005995, without significant drug-related adverse events
  • whose primary care physician agrees that it is appropriate to participate in this study
  • who agree to take only the OROS® (methylphenidate HCl) supplied and no other methylphenidate dosage form or other medications for the treatment of ADHD during the study
  • who are able to comply with the study visit schedule and whose parent(s) and teachers are willing and able to complete the protocol-specified assessments
  • who have normal urinalysis, hematological and blood chemistry values or, if values are outside the normal range, they are determined not clinically significant by the investigator

Exclusion

  • Patients having clinically significant gastrointestinal problems, including narrowing of the gastrointestinal tract
  • having any coexisting medical condition or are taking any medication that is likely to interfere with safe administration of methylphenidate
  • having a known hypersensitivity to methylphenidate
  • having a history of high blood pressure or who have a blood pressure (systolic or diastolic) equal to or greater than the 95th percentile for age, gender and height
  • if female, have begun menstruation

Key Trial Info

Start Date :

Trial Type :

INTERVENTIONAL

End Date :

December 1 1999

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00269815

End Date

December 1 1999

Last Update

June 14 2011

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.